Alfuzosin Hydrochloride Tablet, Extended Release
Product Images NDC 47335-956

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 47335-956). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of Alfuzosin Hydrochloride as depicted in the image, showing molecular bonds and functional groups including methoxy groups and a hydrochloride salt.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A pharmacokinetic line graph showing alfuzosin plasma concentration (ng/mL) over 24 hours comparing fed and fasted states. The fed condition shows a higher peak concentration around 8-10 hours, while the fasted state demonstrates lower, more stable plasma levels. Error bars indicate variability at each time point.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph titled 'Mean Change from Baseline in IPSS Total Symptom Score: Trial 1' comparing mean symptom score change over 84 days of treatment between placebo and Alfuzosin hydrochloride extended-release tablets. The graph shows greater symptom score reduction with Alfuzosin hydrochloride versus placebo, with statistical significance indicated (p < 0.001).*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph displaying the mean change from baseline in IPSS Total Symptom Score over 84 days of treatment. The graph compares placebo (N=152) and alfuzosin hydrochloride extended-release tablets (N=137), showing greater symptom score reduction with the alfuzosin treatment. The x-axis marks days of treatment (0, 28, 56, 84) and the y-axis shows mean change, with statistical significance indicated at day 84 (p < 0.01).*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph showing mean change from baseline in IPSS total symptom score over 84 days of treatment. Two groups are compared: placebo (N=150) represented by triangles and Alfuzosin hydrochloride extended-release tablets (N=151) represented by squares. The graph indicates a greater reduction in symptom score for the Alfuzosin group compared to placebo, with statistical significance marked at p < 0.01 on day 84.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A line graph showing mean change from baseline in peak urine flow rate (mL/s) over days of treatment comparing placebo (N=167) and Alfuzosin hydrochloride extended-release tablets (N=170). The X-axis represents days of treatment (0, 28, 56, 84) and the Y-axis represents mean change in mL/s (range 0 to 3). The graph indicates a higher increase for Alfuzosin hydrochloride versus placebo, with statistical significance (p < 0.001) noted at day 84.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
Line graph showing mean change from baseline in peak urine flow rate (mL/s) over 84 days of treatment comparing Alfuzosin hydrochloride extended-release tablets (10 mg) to placebo. The Alfuzosin group shows a greater increase across all time points, with statistically significant differences indicated by p<0.05 at day 84.*
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
A line graph showing mean change from baseline in peak urine flow rate (mL/s) over days of treatment (0 to 84) comparing placebo (N=150) and Alfuzosin hydrochloride extended-release tablets (N=151). The Alfuzosin group shows a higher increase in flow rate over time compared to placebo, with data points plotted at days 0, 14, 28, 56, and 84. The graph includes a note indicating nonsignificant difference at p > 0.05 at day 84.*
FDA Label Image

Label (Label)

Label (Label)
Label for Alfuzosin Hydrochloride Extended-Release Tablets, 10 mg strength, oral dosage form in tablet extended release. The label indicates the package contains 90 tablets and is distributed by Sun Pharmaceutical Industries, Inc., manufactured by Sun Pharmaceutical Industries Ltd. Storage instructions and dispensing information are also included on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.